KBI Biopharma SA and Selexis SA, both JSR Life Sciences companies, has opened an fully-integrated mammalian contract development and manufacturing services facility in Geneva, Switzerland.
 
The ~94,000 square-foot KBI/Selexis state-of-the-art facility builds on the companies’ existing expertise combining cell line development (CLD) and mammalian cell manufacturing in a single location.  
 
This expansion enables delivery of client programs through increased quality, efficiency, and time savings across a diverse portfolio of molecule formats. KBI and Selexis can provide cell line transfection through cGMP drug manufacturing with Selexis’ specialized high-titer mammalian cell line development technologies and services and KBI’s cGMP bulk drug manufacturing for clinical and commercial requirements.
 
“This expansion in Geneva will provide our global clients with streamlined capabilities to support mammalian-based therapies,” said Mark W. Womack, Chief Executive Officer for KBI Biopharma and Selexis SA. “With a single touchpoint for best-in-class cell line development, process development, and manufacturing, clients experience heightened access to our process and product-based expertise.”
 
He added, “This facility expansion, together with our track record in the space, strengthens our commitment to deliver a seamless experience to the European biopharmaceutical community and clients around the globe.”
 
The fully integrated Selexis and KBI development platform has supported more than 60 clinical development programs with high productivity and robust product quality. 
 
The KBI Biopharma facility will create more than 200 technical positions in development, operations, and quality assurance. The facility includes a suite of analytical testing laboratories and dual 2,000L single-use cGMP manufacturing trains with downstream processes capable of producing 8-10 kg yields per batch.